TG Therapeutics, Inc. announced the submission of a Biologics License Application to the FDA requesting approval of ublituximab, the company’s investigational glycoengineered anti-CD20 monoclonal antibody, as a treatment for patients with relapsing forms of multiple sclerosis.
[TG Therapeutics, Inc.]
Sorry, but the selected Zotpress account can't be found.